Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers. This is an ASCO Meeting Abstract from the 2018 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results